» Articles » PMID: 38085543

Opportunistic Screening With Low-Dose Computed Tomography and Lung Cancer Mortality in China

Abstract

Importance: Despite the recommendations of lung cancer screening guidelines and the evidence supporting the effectiveness of population-based lung screening, a common barrier to effective lung cancer screening is that the participation rates of low-dose computed tomography (LDCT) screening among individuals with the highest risk are not large. There are limited data from clinical practice regarding whether opportunistic LDCT screening is associated with reduced lung-cancer mortality.

Objective: To evaluate whether opportunistic LDCT screening is associated with improved prognosis among adults with lung cancer in mainland China.

Design, Setting, And Participants: This cohort study included patients diagnosed with lung cancer at Weihai Municipal Hospital Healthcare Group, Weihai City, China, from 2016 to 2021. Data were analyzed from January 2022 to February 2023.

Exposures: Data collected included demographic indicators, tumor characteristics, comorbidities, blood indexes, and treatment information. Patients were classified into screened and nonscreened groups on the basis of whether or not their lung cancer diagnosis occurred through opportunistic screening.

Main Outcomes And Measures: Follow-up outcome indicators included lung cancer-specific mortality and all-cause mortality. Propensity score matching (PSM) was adopted to account for potential imbalanced factors between groups. The associations between LDCT screening and outcomes were analyzed using Cox regression models based on the matched data. Propensity score regression adjustment and inverse probability treatment weighting were used for sensitivity analysis.

Results: A total of 5234 patients (mean [SD] baseline age, 61.8 [9.8] years; 2518 [48.1%] female) with complete opportunistic screening information were included in the analytical sample, with 2251 patients (42.91%) receiving their lung cancer diagnosis through opportunistic screening. After 1:1 PSM, 2788 patients (1394 in each group) were finally included. The baseline characteristics of the matched patients were balanced between groups. Opportunistic screening with LDCT was associated with a 49% lower risk of lung cancer death (HR, 0.51; 95% CI, 0.42-0.62) and 46% lower risk of all-cause death (HR, 0.54; 95% CI, 0.45-0.64).

Conclusions And Relevance: In this cohort study of patients with lung cancer, opportunistic lung cancer screening with LDCT was associated with lower lung cancer mortality and all-cause mortality. These findings suggest that opportunistic screening is an important supplement to population screening to improve prognosis of adults with lung cancer.

Citing Articles

Lung cancer screening eligibility and recruitment during routine care by pulmonologists: barriers and new opportunities in the Brazilian public healthcare system.

Svartman F, Azambuja M, Palma E, Sartori A, Leite M J Bras Pneumol. 2024; 50(3):e20240071.

PMID: 39166588 PMC: 11449590. DOI: 10.36416/1806-3756/e20240071.


Estimating the Effects of Cancer Screening in Clinical Practice Settings: The Role of Selective Uptake and Suboptimal Adherence along the Cancer Screening Continuum.

Lund J, Rivera M, Su I, Long J, Chen X, Pak J Cancer Epidemiol Biomarkers Prev. 2024; 33(8):984-988.

PMID: 39012954 PMC: 11351907. DOI: 10.1158/1055-9965.EPI-23-1491.


Noteworthy impacts of COVID-19 pandemic on cancer screening: A systematic review.

Wang H, Yang M, Xiong W, Wang Q, Zheng B, Bai Y Fundam Res. 2024; 4(3):484-494.

PMID: 38933198 PMC: 11197616. DOI: 10.1016/j.fmre.2023.12.016.

References
1.
Wood D, Kazerooni E, Aberle D, Berman A, Brown L, Eapen G . NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.2022. J Natl Compr Canc Netw. 2022; 20(7):754-764. DOI: 10.6004/jnccn.2022.0036. View

2.
Tranberg M, Larsen M, Mikkelsen E, Svanholm H, Andersen B . Impact of opportunistic testing in a systematic cervical cancer screening program: a nationwide registry study. BMC Public Health. 2015; 15:681. PMC: 4508820. DOI: 10.1186/s12889-015-2039-0. View

3.
Huo J, Shen C, Volk R, Shih Y . Use of CT and Chest Radiography for Lung Cancer Screening Before and After Publication of Screening Guidelines: Intended and Unintended Uptake. JAMA Intern Med. 2017; 177(3):439-441. PMC: 5893328. DOI: 10.1001/jamainternmed.2016.9016. View

4.
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

5.
Krist A, Davidson K, Mangione C, Barry M, Cabana M, Caughey A . Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement. JAMA. 2021; 325(10):962-970. DOI: 10.1001/jama.2021.1117. View